Human immunodeficiency virus type 1 vpr gene induces phenotypic effects similar to those of the DNA alkylating agent, nitrogen mustard

Journal of Virology

Volumn 71, Issue 5, 1997, Pages 3961-3971

  Poon, Betty ^a   Jowett, Jeremy B M ^a   Stewart, Sheila A ^a   Armstrong, Robert W ^b,c   Rishton, Gilbert M ^c   Chen, Irvin S Y ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMETHINE; METHYLXANTHINE DERIVATIVE; PHOSPHOTRANSFERASE;

ARTICLE; CELL CYCLE G2 PHASE; DNA DAMAGE; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; MITOSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

EID: 0030951420     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.71.5.3961-3971.1997     Document Type: Article

References (48)

1. Aviado, D. M., and H. R. Dettelbach. 1984. Pharmacology of pentoxifylline a hemorrhealogic agent for the treatment of intermittent claudication. Angiology 35:407-417.
2. Balliet, J. W., D. L. Kolson, G. Eiger, F. M. Kim, K. A. McGann, A. Srinivasan, and R. Collman. 1994. Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: mutational analysis of a primary HIV-1 isolate. Virology 200:623-631.
3. 2 accumulation by a mechanism which differs from DNA damage checkpoint control. J. Virol. 70:2324-2331.
4. Bouhamdan, M., S. Benichou, F. Rey, J.-M. Navarro, I. Agostini, B. Spire, J. Camonis, G. Slupphaug, R. Vigne, R. Benarous, and J. Sire. 1996. Human immunodeficiency virus type 1 Vpr protein binds to the uracil DNA glycosylase DNA repair enzyme. J. Virol. 70:697-704.
5. Cohen, E. A., E. F. Terwilliger, Y. Jalinoos, J. Proulx, J. G. Sodroski, and W. A. Haseltine. 1990. Identification of HIV-1 vpr product and function. J. Acquired Immune Defic. Syndr. 3:11-18.
6. Collins, J. M., D. E. Berry, and C. S. Cobbs. 1977. Structure of parental deoxyribonucleic acid of synchronized HeLa cells. Biochemistry 16:5438-5444.
7. Connor, R. I., B. K. Chen, S. Choe, and N. R. Landau. 1995. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206:935-944.
8. Daly, J. W. 1993. Mechanism of action of caffeine, p. 97-149. In S. Garattini (ed.), Caffeine, coffee, and health. Raven Press, New York, N.Y.
9. Dezube, B. J. 1994. Pentoxifylline for the treatment of infection with human immunodeficiency virus. Clin. Infect. Dis. 18:285-287.
10. Dezube, B. J., A. B. Pardee, B. Chapman, L. A. Beckett, J. A. Korvick, W. J. Novick, J. Chiurco, P. Kasdan, C. M. Ahlers, L. T. Ecto, C. S. Crumpacker, and the NIAID AIDS Clinical Trials Group. 1993. Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. J. Acquired Immune Defic. Syndr. 6:787-794.
11. Draetta, G., and D. Beach. 1988. Activation of cdc2 protein kinase during mitosis in human cells: cell-cycle-dependent phosphorylation and subunit rearrangement. Cell 54:17-26.
12. Ernst, E. 1994. Pentoxifylline for intermittent claudication. A critical review. Angiology 45:339-345.
13. Fingert, H. J., J. D. Chang, and A. B. Pardee. 1986. Cytotoxic, cell cycle, and chromosomal effects of methylxanthines in human tumor cells treated with alkylating agents. Cancer Res. 46:2463-2467.
14. Fingert, H. J., A. T. Pu, Z. Chen, P. B. Googe, M. C. Alley, and A. B. Pardee. 1988. In vivo and in vitro enhanced antitumor effects by pentoxifylline in human cancer cells treated with thiotepa. Cancer Res. 48:4375-4381.
15. Fletcher, T. M., III, B. Brichacek, N. Sharova, M. A. Newman, G. Stivahtis, P. M. Sharp, M. Emerman, B. H. Hahn, and M. Stevenson. 1996. Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2-SIV-SM. EMBO J. 15:6155-6165.
16. Gibbs, J. S., A. Lackner, S. M. Lang, M. A. Simon, P. K. Schgal, M. D. Daniel, and R. C. Desrosiers. 1995. Progression to AIDS in the absence of a gene for vpr or vpx. J. Virol. 69:2378-2383.
17. Hattori, N., F. Michaels, K. Fargnoli, L. Marcon, R. C. Gallo, and G. Franchini. 1990. The human immunodeficiency virus type 2 vpr gene is essential for productive infection of human macrophages. Proc. Natl. Acad. Sci. USA 87:8080-8084.
18. cdc2 activity. J. Virol. 69:6705-6711.
19. Heinzinger, N. K., M. I. Bukrinsky, S. A. Haggerty, A. M. Ragland, V. Kewalramani, M.-A. Lee, H. E. Gendelman, L. Ratner, M. Stevenson, and M. Emerman. 1994. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc. Natl. Acad. Sci. USA 91:7311-7315.
20. Hoch, J., S. M. Lang, M. Weeger, C. Stahl-Hennig, C. Coulibaly, U. Dittmer, G. Hunsmann, D. Fuchs, J. Müller, S. Sopper, B. Fleckenstein, and K. T. Überla. 1995. vpr deletion mutant of simian immunodeficiency virus induces AIDS in rhesus monkeys. J. Virol. 69:4807-4813.
21. Jowett, J. B. M., V. Planelles, B. Poon, N. P. Shah, M. L. Chen, and I. S. Y. Chen. 1995. The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. J. Virol. 69:6304-6313.
22. gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles. J. Virol. 69:2759-2764.
23. Lang, S. M., M. Weeger, C. Stahl-Hennig, C. Coulibaly, G. Hunsmann, J. Müller, H. Müller-Hermelink, D. Fuchs, H. Wachter, M. M. Daniel, R. C. Desrosiers, and B. Fleckenstein. 1993. Importance of vpr for infection of rhesus monkeys with simian immunodeficiency virus. J. Virol. 67:902-912.
24. Lau, C. C., and A. B. Pardee. 1982. Mechanism by which caffeine potentiates lethality of nitrogen mustard. Proc. Natl. Acad. Sci. USA 79:2942-2946.
25. Maity, A., W. G. McKenna, and R. J. Muschel. 1994. The molecular basis for cell cycle delays following ionizing radiation: a review. Radiother. Oncol. 31:1-13.
26. Marangos, P. J. 1985. Differential effects of caffeine on brain adenosine receptors and uptake sites, p. 191-198. In V. Stefanovich, K. Rudolphi, and P. Shubert (ed.), Adenosine: receptors and modulation of cell function. IRL Press Ltd., Oxford, England.
27. Murnane, J. P. 1995. Cell cycle regulation in response to DNA damage in mammalian cells: a historical perspective. Cancer Metastasis Rev. 14:17-29.
28. Murnane, J. P., J. E. Byfield, J. F. Ward, and P. Calabro-Jones. 1980. Effects of methylated xanthines on mammalian cells treated with bifunctional alkylating agents. Nature 285:326-328.
29. Murray, A. W. 1992. Creative blocks: cell-cycle checkpoints and feedback controls. Nature 359:599-604.
30. Norbury, C., and P. Nurse. 1992. Animal cell cycles and their control. Annu. Rev. Biochem. 61:441-470.
31. 2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin Bl/cdc2-kinase complexes differently. J. Biol. Chem. 268:8298-8308.
32. O'Connor, P. M., D. K. Ferris, G. A. White, J. Pines, T. Hunter, D. L. Longo, and K. W. Kohn. 1992. Relationships between cdc2 kinase, DNA cross-linking, and cell cycle perturbations induced by nitrogen mustard. Cell Growth Differ. 3:43-52.
33. Paxton, W., R. I. Connor, and N. R. Landau. 1993. Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis. J. Virol. 67:7229-7237.
34. Planelles, V., F. Bachelerie, J. B. M. Jowett, A. Haislip, Y. Xie, P. Banooni, T. Masuda, and I. S. Y. Chen. 1995. Fate of the human immunodeficiency virus type 1 provirus in infected cells: a role for vpr. J. Virol. 69:5883-5889.
35. Planelles, V., J. B. M. Jowett, Q.-X. Li, Y. Xie, B. Hahn, and I. S. Y. Chen. 1996. Vpr-induced cell cycle arrest is conserved among primate lentiviruses. J. Virol. 70:2516-2524.
36. cdc2-cyclin B. J. Virol. 69:6859-6864.
37. Rogel, M. E., L. I. Wu, and M. Emerman. 1995. The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. J. Virol. 69:882-888.
38. Schmid, I., C. H. Uittenbogaart, and J. V. Giorgi. 1991. A gentle fixation and permeabilization method for combined cell surface and intracellular staining with improved precision in DNA quantification. Cytometry 12:279-285.
39. Sharp, P. M., E. Bailes, M. Stevenson, M. Emerman, and B. H. Hahn. 1996. Gene acquisition in HIV and SIV. Nature 383:586-587.
40. Sheldrick, K. S., and A. M. Carr. 1993. Feedback controls and G2 checkpoints: fission yeast as a model system. BioEssays 15:775-782.
41. Slupphaug, G., L. C. Olsen, D. Helland, R. Aasland, and H. E. Krokan. 1991. Cell cycle regulation and in vitro hybrid arrest analysis of the major human uracil-DNA glycosylase. Nucleic Acids Res. 19:5131-5137.
42. Solomon, M. J. 1993. Activation of the various cyclin/cdc2 protein kinases. Curr. Opin. Cell Biol. 5:180-186.
43. Stewart, S. A., B. Poon, J. B. M. Jowett, and I. S. Y. Chen. Human immunodeficiency virus Vpr induces apoptosis following cell cycle arrest. J. Virol., in press.
44. Teicher, B. A., S. A. Holden, T. S. Herman, R. Epelbaum, A. B. Pardee, and B. Dezube. 1991. Efficacy of pentoxifylline as a modulator of alkylating agent activity in vitro and in vivo. Anticancer Res. 11:1555-1560.
45. Tristam, H., C. Marshall, A. Karpas, and F. Hill. 1992. Evolution of the primate lentiviruses: evidence from vpx and vpr. EMBO J. 11:3405-3412.
46. Vilpo, J. A., and L. M. Vilpo. 1989. Normal uracil-DNA glycosylase activity in Bloom's syndrome cells. Mutat. Res. 210:59-62.
47. Westervelt, P., T. Henkel, D. B. Trowbridge, J. Orenstein, J. Heuser, H. E. Gendelman, and L. Ratner. 1992. Dual regulation of silent and productive infection in monocytes by distinct human immunodeficiency virus type 1 determinants. J. Virol. 66:3925-3931.
48. Zhao, Y., J. Cao, M. R. G. O'Gorman, M. Yu, and R. Yogev. 1996. Effect of human immunodeficiency virus type 1 protein R (vpr) gene expression on basic cellular function of fission yeast Schizosaccharomyces pombe. J. Virol. 70:5821-5826.